ADMA Biologics (ADMA) executive compensation, 2026 proxy

Adam S. Grossman, President, Chief Executive Officer and Director, was paid $10.2M in 2025, up 29% from $7.9M the year before. The CEO-to-median-employee pay ratio was 120:1, on median employee pay of $85,586.

Filed
April 15, 2026
Annual meeting
June 2, 2026
Pay year
2025
Named executives
4
CEO total pay
$10.2M+29% vs prior year
CEO to median employee
120:1median $85,586
CEO pay in equity
79%$8.1M in awards
CEO Base Salary
$925,000For fiscal year 2025
CEO Non-Equity Incentive
$1,156,250Paid in March 2026
CEO Stock Awards
$4,049,994Grant date fair value
CEO Option Awards
$4,049,998Grant date fair value
Total Employees
633Excluding CEO as of Dec 31, 2024

How Grossman was paid

$10.2M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary9%Stock awards40%Option awards40%Non-equity incentive11%All other compensation1%

Named executive officers

ExecutiveTotal
Adam S. GrossmanPresident, Chief Executive Officer and Director$10,237,326
Kaitlin KestenbergChief Operating Officer & Senior Vice President, Compliance$3,488,647
Paul Terence Kohler, Jr.Current Chief Financial Officer and Treasurer$2,296,949
Brad L. TadeFormer Executive Vice President and Chief Financial Officer$2,823,630

What changed and why

  • $10.2MAdam S. Grossman received total compensation of $10,237,326 for fiscal 2025, representing an increase from $7,918,734 in fiscal 2024.
  • Stock and option awards represented the largest portions of the CEO total compensation package for 2025.
  • Annual bonus awards for 2025 were paid based on established corporate performance goals and individual performance.
  • Paul Terence Kohler, Jr. was appointed as Chief Financial Officer and Treasurer during fiscal 2025.
  • Brad L. Tade transitioned from Chief Financial Officer to a consulting role effective February 25, 2026.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.